At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 143 enrolled
Drug / intervention
Clazakizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
In Brief
A Phase 2 clinical trial evaluating Clazakizumab and Placebo (Matching with Clazakizumab) for Rheumatoid Arthritis. Completed, enrolled 143 participants across 55 sites in 9 countries.
Detailed Summary
The primary purpose of this study is to identify an appropriate dose of study medication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Canada, France, Hungary, Italy, Japan, Mexico, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
Primary CompletionJun 2013
First PostedDec 2013
Study CompletionJun 2015
TodayJul 2026
First PostedDec 19, 2013
Enrollment StartJun 1, 2012
Primary CompletionJun 1, 2013
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.5 years ago
Interventions
Clazakizumabdrug
Placebo (Matching with Clazakizumab)drug